We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TSLA:NASDAQTesla, Inc. Analysis

Data as of 2026-05-28 - not real-time

$440.36

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Tesla’s technical picture shows a bullish MACD histogram (0.59) and an RSI of 63, suggesting upward momentum while the price sits just below the calculated resistance of $453.40 and well above the support of $368.17, indicating limited upside in the near term. The stock’s volatility is exceptionally high at 41.66% over 30 days and a beta of 2.06, which together with a max drawdown of –29.93% and a fear‑greed index of 92.34 (Extreme Greed) flag considerable risk, especially as trading volume is on a decreasing trend. Fundamental metrics reinforce an overvalued picture: a trailing P/E of 400.33, forward P/E of 175.46, and a price‑to‑book of 20.11 place the market price ($440.36) far above the DCF fair value ($43.06), while the PE‑ratio and the lack of dividend (0% yield) underscore that earnings are not supporting the current valuation. Material news items – the speculative Tesla‑SpaceX merger talk, a 46.5% YoY European sales jump, the robotaxi/Optimus narrative, the upcoming Q1 results release, and a large‑scale vehicle recall – all amplify growth expectations but also add regulatory and execution uncertainty. Consequently, while the stock’s growth narrative remains compelling, the confluence of high volatility, elevated beta, extreme market greed, and a stark valuation gap suggests caution for short‑term traders and a nuanced hold‑or‑buy stance for longer horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • MACD bullish histogram
  • price near resistance $453.40
  • decreasing volume trend

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Tesla‑SpaceX merger speculation
  • 46.5% YoY Europe sales rise
  • robotaxi narrative driving demand

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Extreme Greed fear index 92.34
  • high beta 2.06 indicating market sensitivity
  • potential DCF fair value gap

Key Metrics & Analysis

Financial Health

Revenue Growth15.80%
Profit Margin3.95%
P/E Ratio400.3
ROE4.90%
ROA2.23%
Debt/Equity18.74
P/B Ratio20.1
Op. Cash Flow$16.5B
Free Cash Flow$5.3B

Technical Analysis

TrendNeutral
RSI63.0
Support$368.17
Resistance$453.40
MA 20$415.22
MA 50$390.08
MA 200$411.14
MACDBullish
VolumeDecreasing
Fear & Greed Index92.34

Valuation

Fair Value$43.06
Target Price$411.89
Upside/Downside-6.47%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.06
Volatility41.66%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.